Rituximab Therapy for Primary Sjögren's Syndrome: An Open‐Label Clinical Trial and Mechanistic Analysis
Open Access
- 17 January 2013
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 65 (4), 1097-1106
- https://doi.org/10.1002/art.37850
Abstract
Objective To study the safety and clinical efficacy of rituximab therapy for primary Sjögren's syndrome, as well as to investigate its mechanisms. Methods Patients with primary Sjögren's syndrome were enrolled in an open-label trial, were given rituximab (1 gm) infusions on days 1 and 15, and were monitored through week 52. The primary end point was safety, with secondary end points evaluating clinical and biologic efficacy. Blood was obtained for enumeration of lymphocyte subsets, measurement of serum autoantibody and BAFF levels, and analysis of gene expression. Results Twelve female patients with primary Sjögren's syndrome were administered rituximab. They had a median age of 51 years (range 34–69 years) and a median disease duration of 8.0 years (range 2–18 years). We observed no unexpected toxicities from the rituximab therapy. Modest improvements were observed at week 26 in patient-reported symptoms of fatigue and oral dryness, with no significant improvement in the objective measures of lacrimal and salivary gland function. The recovery of blood B cells following the nadir from rituximab therapy was characterized by a predominance of transitional B cells and a lack of memory B cells. While blood B cell depletion was associated with an increase in serum BAFF levels, no significant changes were observed in the levels of serum anti-Ro/SSA, anti-La/SSB, and anti–type 3 muscarinic acetylcholine receptor autoantibodies or in the blood interferon signature. Conclusion In patients with primary Sjögren's syndrome, a single treatment course of rituximab was not associated with any unexpected toxicities and led to only modest clinical benefits despite effective depletion of blood B cells.Keywords
This publication has 36 references indexed in Scilit:
- Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expressionAnnals Of The Rheumatic Diseases, 2012
- Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2011
- Significance of B cells and B cell clonality in Sjögren's syndromeArthritis & Rheumatism, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trialArthritis & Rheumatism, 2009
- Peripheral blood gene expression profiling in Sjögren's syndromeGenes & Immunity, 2009
- Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF productionAnnals Of The Rheumatic Diseases, 2007
- Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2007
- Detection of anti–type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjögren's syndrome patients by use of a transfected cell line assayArthritis & Rheumatism, 2004
- Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndromeArthritis & Rheumatism, 2004